Skip to main content
SpringerLink
Log in

Radioactive Iodine for Papillary Thyroid Carcinoma

  • Protocol
  • First Online:
Papillary Thyroid Carcinoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2534))

Abstract

Radioactive iodine is given after total thyroidectomy for remnant ablation or treatment of residual/metastatic disease. The decision and dose of radioactive iodine should be in a personalized and patient-specific approach, taking account the clinical-pathological features, risk stratification, patient’s preference, and facilities of the institutions. We review the principles and use of radioactive iodine in differentiated thyroid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133

    Article  PubMed  PubMed Central  Google Scholar 

  2. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR (2014) British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 81(Suppl 1):1–122

    Article  CAS  Google Scholar 

  3. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E, European Association of Nuclear Medicine (EANM) (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959

    Article  CAS  PubMed  Google Scholar 

  4. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A, ESMO Guidelines Committee (2009) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1856–1883

    Article  Google Scholar 

  5. Verburg FA, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ, Langsteger W, Luster M (2016) Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 43:1001–1005

    Article  PubMed  Google Scholar 

  6. Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, Dillehay G, Draganescu C, Flux G, Führer D, Giovanella L, Greenspan B, Luster M, Muylle K, JWA S, Van Nostrand D, Verburg FA, Hegedüs L (2019) controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: a Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29:461–470

    Article  PubMed  Google Scholar 

  7. Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Catargi BN, Do Cao C, Kelly A, Barge ML, Dygay I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, Giraudet AL, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Anne D, Schwartz C, Velayoudoum F, Schlumberger MJ, Leenhardt L, Borget I (2021) Estimabl2: is there a need for radioiodine ablation in low risk differentiated thyroid cancer (DTC) patients?: results from the French randomized phase III prospective trial on 776 patients (NCT 01837745). J Endocr Soc 5(Supplement_1):A875

    Article  PubMed Central  Google Scholar 

  8. Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, Rusu D, Godbert Y, Buffet C, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Toubert ME, Kelly A, Benhamou E, Borget I (2018) Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol 6:618–626

    Article  PubMed  Google Scholar 

  9. Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A (2019) Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol 7:44–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Toubert ME, Hindie E, Rampin L, Al-Nahhas A, Rubello D (2007) Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome. Nucl Med Rev Cent East Eur 10:106–109

    PubMed  Google Scholar 

  11. Hirsch D, Levy S, Tsvetov G, Gorshtein A, Slutzky-Shraga I, Akirov A, Robenshtok E, Shimon I, Benbassat CA (2017) Long-term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases. Endocr Pract 23:1193–1200

    Article  PubMed  Google Scholar 

  12. Slook O, Levy S, Slutzky-Shraga I, Tsvetov G, Robenshtok E, Shimon I, Benbassat C, Hirsch D (2019) Long-term outcomes and prognostic factors in patients with differentiated thyroid carcinoma and bone metastases. Endocr Pract 25:427–437

    Article  PubMed  Google Scholar 

  13. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, Togashi K, Itasaka S, Hiraoka M, Misaki T, Konishi J (2011) Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med 52:683–689

    Article  PubMed  Google Scholar 

  14. Suman P, Wang CH, Abadin SS, Block R, Raghavan V, Moo-Young TA, Prinz RA, Winchester DJ (2016) Timing of radioactive iodine therapy does not impact overall survival in high-risk papillary thyroid carcinoma. Endocr Pract 22:822–831

    Article  PubMed  Google Scholar 

  15. Ahn J, Jin M, Song E, Jeon MJ, Kim TY, Ryu JS, Kim WB, Shong YK, Han JM, Kim WG (2000) Clinical outcomes after early and delayed radioiodine remnant ablation in patients with low-risk papillary thyroid carcinoma: propensity score matching analysis. Endocrinol Metab (Seoul) 35:830–837

    Article  Google Scholar 

  16. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, Eftekhari M (2014) Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 35:808–817

    Article  CAS  PubMed  Google Scholar 

  17. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888–896

    Article  CAS  PubMed  Google Scholar 

  19. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS (2010) Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20:173–179

    Article  PubMed  Google Scholar 

  20. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E (2009) Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 160:431–436

    Article  CAS  PubMed  Google Scholar 

  21. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol 71:115–123

    Article  CAS  Google Scholar 

  22. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932

    Article  CAS  PubMed  Google Scholar 

  23. Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F (2010) Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database Syst Rev 2010:CD008302

    PubMed Central  Google Scholar 

  24. Rudavsky AZ, Freeman LM (1997) Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 82:11–14

    Article  CAS  PubMed  Google Scholar 

  25. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F (2005) rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49–64

    Article  CAS  PubMed  Google Scholar 

  26. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L (2013) Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. Endocr Pract 19:139–148

    Article  PubMed  Google Scholar 

  27. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C (2000) Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640–3645

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong

    Wendy W. L. Chan & Dora L. W. Kwong

Authors
  1. Wendy W. L. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dora L. W. Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy W. L. Chan .

Editor information

Editors and Affiliations

  1. School of Medicine and Dentistry and Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

    Alfred K. Lam

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Chan, W.W.L., Kwong, D.L.W. (2022). Radioactive Iodine for Papillary Thyroid Carcinoma. In: Lam, A.K. (eds) Papillary Thyroid Carcinoma. Methods in Molecular Biology, vol 2534. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2505-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-2505-7_16

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-2504-0

  • Online ISBN: 978-1-0716-2505-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation